Dosing strategies for conversion of haemodialysis patients from short‐acting erythropoiesis stimulating agents to once‐monthly C.E.R.A.: experience from the MIRACEL study
Identifieur interne : 000360 ( Main/Exploration ); précédent : 000359; suivant : 000361Dosing strategies for conversion of haemodialysis patients from short‐acting erythropoiesis stimulating agents to once‐monthly C.E.R.A.: experience from the MIRACEL study
Auteurs : F. Dellanna [Allemagne] ; R. E. Winkler [Allemagne] ; F. Bozkurt [Allemagne] ; V. Schettler [Allemagne] ; S. Graf [Allemagne] ; N. Bockreiss [Allemagne] ; D. Fliser [Allemagne]Source :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2011-01.
English descriptors
- Teeft :
- Adverse event, Adverse events, Alfa, Blackwell publishing, Chronic kidney disease, Clin, Clin pract, Continuous erythropoietin receptor activator, Darbepoetin, Darbepoetin alfa, Dialysis patients, Dos, Dose, Dose changes, Dose decrease, Dose decreases, Dose increase, Dosing, Epoetin, Epoetin alfa, Erythropoietin, Evaluation phase, Evaluation phases, Exclusion criteria, Haemodialysis, Haemodialysis patients, Haemoglobin, Hemodialysis patients, Initial dose, January, Median, Miracel, Miracel study, Monthly experience, Nephrol, Nephrol dial transplant, Pract, Practice guidelines, Receptor, Roche, Safety population, Screening phase, Serum ferritin, Study entry, Syringe, Target range, Target ranges, Titration, Titration evaluation phases, Titration phase, Transferrin saturation.
Abstract
Aims: To analyse the impact of dosing decisions for continuous erythropoietin receptor activator (C.E.R.A.), a continuous erythropoietin receptor activator.
Methods: This was a prospective, multicentre, single‐arm study in haemodialysis patients receiving epoetin alfa/beta or darbepoetin alfa. After a 2‐month screening phase, patients were converted to monthly C.E.R.A. using pre‐filled syringes during a 5‐month titration phase and a 2‐month evaluation phase.
Results: Four hundred and twenty‐four eligible patients were converted to C.E.R.A. Mean Hb were 11.7 ± 0.7, 11.7 ± 0.8 and 11.5 ± 0.8 g/dl during screening, titration and evaluation, respectively. C.E.R.A. starting dose was 125 μg (n = 311) or 200 μg (n = 106), with corresponding final doses of 129 ± 61 μg and 203 ± 58 μg. The mean number of C.E.R.A. dose decreases and increases were 0.9 ± 1.0 and 1.1 ± 1.0 per patient, respectively. Hb rarely exceeded 12.5 g/dl after a C.E.R.A. dose increase (< 8%) and remained ≥ 11 g/dl after a dose reduction on approximately three‐quarters of occasions. Among the 53 occasions where Hb decreased ≥ 2 g/dl between two consecutive visits, the previous dose had been withheld (n = 9), concomitant blood loss, coagulopathy or infection was present (n = 13), or iron parameters were low (n = 17). There were 104 adverse events/month during screening, and 45/month during the titration/evaluation phases. Serious adverse events occurred in 18.0 and 21.0 patients/month during the screening and titration/evaluation phases, respectively.
Conclusion: Switching haemodialysis patients from shorter‐acting ESA to once‐monthly C.E.R.A. using pre‐filled syringes is straightforward, and Hb levels remain stable. Starting dose recommendations and dose changes correlated well with the clinical setting. Collateral factors such as infection or aggravating concomitant medical conditions should be taken into account.
Url:
DOI: 10.1111/j.1742-1241.2010.02551.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000842
- to stream Istex, to step Curation: 000801
- to stream Istex, to step Checkpoint: 000221
- to stream Main, to step Merge: 000360
- to stream Main, to step Curation: 000360
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dosing strategies for conversion of haemodialysis patients from short‐acting erythropoiesis stimulating agents to once‐monthly C.E.R.A.: experience from the MIRACEL study</title><author><name sortKey="Dellanna, F" sort="Dellanna, F" uniqKey="Dellanna F" first="F." last="Dellanna">F. Dellanna</name></author><author><name sortKey="Winkler, R E" sort="Winkler, R E" uniqKey="Winkler R" first="R. E." last="Winkler">R. E. Winkler</name></author><author><name sortKey="Bozkurt, F" sort="Bozkurt, F" uniqKey="Bozkurt F" first="F." last="Bozkurt">F. Bozkurt</name></author><author><name sortKey="Schettler, V" sort="Schettler, V" uniqKey="Schettler V" first="V." last="Schettler">V. Schettler</name></author><author><name sortKey="Graf, S" sort="Graf, S" uniqKey="Graf S" first="S." last="Graf">S. Graf</name></author><author><name sortKey="Bockreiss, N" sort="Bockreiss, N" uniqKey="Bockreiss N" first="N." last="Bockreiss">N. Bockreiss</name></author><author><name sortKey="Fliser, D" sort="Fliser, D" uniqKey="Fliser D" first="D." last="Fliser">D. Fliser</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4FB9DAD73FF7779A21A20F69F7014643B22C7E89</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1742-1241.2010.02551.x</idno><idno type="url">https://api.istex.fr/document/4FB9DAD73FF7779A21A20F69F7014643B22C7E89/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000842</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000842</idno><idno type="wicri:Area/Istex/Curation">000801</idno><idno type="wicri:Area/Istex/Checkpoint">000221</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000221</idno><idno type="wicri:doubleKey">1368-5031:2011:Dellanna F:dosing:strategies:for</idno><idno type="wicri:Area/Main/Merge">000360</idno><idno type="wicri:Area/Main/Curation">000360</idno><idno type="wicri:Area/Main/Exploration">000360</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dosing strategies for conversion of haemodialysis patients from short‐acting erythropoiesis stimulating agents to once‐monthly C.E.R.A.: experience from the MIRACEL study</title><author><name sortKey="Dellanna, F" sort="Dellanna, F" uniqKey="Dellanna F" first="F." last="Dellanna">F. Dellanna</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Dialysezentrum Karlstrasse, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Winkler, R E" sort="Winkler, R E" uniqKey="Winkler R" first="R. E." last="Winkler">R. E. Winkler</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Gemeinschaftspraxis für Innere Medizin, Nephrologie, Rostock</wicri:regionArea><wicri:noRegion>Rostock</wicri:noRegion><wicri:noRegion>Rostock</wicri:noRegion></affiliation></author><author><name sortKey="Bozkurt, F" sort="Bozkurt, F" uniqKey="Bozkurt F" first="F." last="Bozkurt">F. Bozkurt</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Gemeinschaftspraxis für Innere Medizin, Nephrologie, Daun</wicri:regionArea><wicri:noRegion>Daun</wicri:noRegion><wicri:noRegion>Daun</wicri:noRegion></affiliation></author><author><name sortKey="Schettler, V" sort="Schettler, V" uniqKey="Schettler V" first="V." last="Schettler">V. Schettler</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Nephrologisches Zentrum Göttingen, Göttingen</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Göttingen</settlement></placeName></affiliation></author><author><name sortKey="Graf, S" sort="Graf, S" uniqKey="Graf S" first="S." last="Graf">S. Graf</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>KfH‐Nierenzentrum, Fulda</wicri:regionArea><wicri:noRegion>Fulda</wicri:noRegion><wicri:noRegion>Fulda</wicri:noRegion></affiliation></author><author><name sortKey="Bockreiss, N" sort="Bockreiss, N" uniqKey="Bockreiss N" first="N." last="Bockreiss">N. Bockreiss</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>KfH‐Nierenzentrum, Oberschleissheim</wicri:regionArea><wicri:noRegion>Oberschleissheim</wicri:noRegion><wicri:noRegion>Oberschleissheim</wicri:noRegion></affiliation></author><author><name sortKey="Fliser, D" sort="Fliser, D" uniqKey="Fliser D" first="D." last="Fliser">D. Fliser</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine IV, Saarland University Medical Centre, Homburg/Saar</wicri:regionArea><wicri:noRegion>Homburg/Saar</wicri:noRegion><wicri:noRegion>Homburg/Saar</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Clinical Practice</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-01">2011-01</date><biblScope unit="volume">65</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="64">64</biblScope><biblScope unit="page" to="72">72</biblScope></imprint><idno type="ISSN">1368-5031</idno></series><idno type="istex">4FB9DAD73FF7779A21A20F69F7014643B22C7E89</idno><idno type="DOI">10.1111/j.1742-1241.2010.02551.x</idno><idno type="ArticleID">IJCP2551</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse event</term><term>Adverse events</term><term>Alfa</term><term>Blackwell publishing</term><term>Chronic kidney disease</term><term>Clin</term><term>Clin pract</term><term>Continuous erythropoietin receptor activator</term><term>Darbepoetin</term><term>Darbepoetin alfa</term><term>Dialysis patients</term><term>Dos</term><term>Dose</term><term>Dose changes</term><term>Dose decrease</term><term>Dose decreases</term><term>Dose increase</term><term>Dosing</term><term>Epoetin</term><term>Epoetin alfa</term><term>Erythropoietin</term><term>Evaluation phase</term><term>Evaluation phases</term><term>Exclusion criteria</term><term>Haemodialysis</term><term>Haemodialysis patients</term><term>Haemoglobin</term><term>Hemodialysis patients</term><term>Initial dose</term><term>January</term><term>Median</term><term>Miracel</term><term>Miracel study</term><term>Monthly experience</term><term>Nephrol</term><term>Nephrol dial transplant</term><term>Pract</term><term>Practice guidelines</term><term>Receptor</term><term>Roche</term><term>Safety population</term><term>Screening phase</term><term>Serum ferritin</term><term>Study entry</term><term>Syringe</term><term>Target range</term><term>Target ranges</term><term>Titration</term><term>Titration evaluation phases</term><term>Titration phase</term><term>Transferrin saturation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Aims: To analyse the impact of dosing decisions for continuous erythropoietin receptor activator (C.E.R.A.), a continuous erythropoietin receptor activator.</div><div type="abstract">Methods: This was a prospective, multicentre, single‐arm study in haemodialysis patients receiving epoetin alfa/beta or darbepoetin alfa. After a 2‐month screening phase, patients were converted to monthly C.E.R.A. using pre‐filled syringes during a 5‐month titration phase and a 2‐month evaluation phase.</div><div type="abstract">Results: Four hundred and twenty‐four eligible patients were converted to C.E.R.A. Mean Hb were 11.7 ± 0.7, 11.7 ± 0.8 and 11.5 ± 0.8 g/dl during screening, titration and evaluation, respectively. C.E.R.A. starting dose was 125 μg (n = 311) or 200 μg (n = 106), with corresponding final doses of 129 ± 61 μg and 203 ± 58 μg. The mean number of C.E.R.A. dose decreases and increases were 0.9 ± 1.0 and 1.1 ± 1.0 per patient, respectively. Hb rarely exceeded 12.5 g/dl after a C.E.R.A. dose increase (< 8%) and remained ≥ 11 g/dl after a dose reduction on approximately three‐quarters of occasions. Among the 53 occasions where Hb decreased ≥ 2 g/dl between two consecutive visits, the previous dose had been withheld (n = 9), concomitant blood loss, coagulopathy or infection was present (n = 13), or iron parameters were low (n = 17). There were 104 adverse events/month during screening, and 45/month during the titration/evaluation phases. Serious adverse events occurred in 18.0 and 21.0 patients/month during the screening and titration/evaluation phases, respectively.</div><div type="abstract">Conclusion: Switching haemodialysis patients from shorter‐acting ESA to once‐monthly C.E.R.A. using pre‐filled syringes is straightforward, and Hb levels remain stable. Starting dose recommendations and dose changes correlated well with the clinical setting. Collateral factors such as infection or aggravating concomitant medical conditions should be taken into account.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Basse-Saxe</li><li>District de Düsseldorf</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Düsseldorf</li><li>Göttingen</li></settlement></list><tree><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Dellanna, F" sort="Dellanna, F" uniqKey="Dellanna F" first="F." last="Dellanna">F. Dellanna</name></region><name sortKey="Bockreiss, N" sort="Bockreiss, N" uniqKey="Bockreiss N" first="N." last="Bockreiss">N. Bockreiss</name><name sortKey="Bozkurt, F" sort="Bozkurt, F" uniqKey="Bozkurt F" first="F." last="Bozkurt">F. Bozkurt</name><name sortKey="Fliser, D" sort="Fliser, D" uniqKey="Fliser D" first="D." last="Fliser">D. Fliser</name><name sortKey="Graf, S" sort="Graf, S" uniqKey="Graf S" first="S." last="Graf">S. Graf</name><name sortKey="Schettler, V" sort="Schettler, V" uniqKey="Schettler V" first="V." last="Schettler">V. Schettler</name><name sortKey="Winkler, R E" sort="Winkler, R E" uniqKey="Winkler R" first="R. E." last="Winkler">R. E. Winkler</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sarre/explor/MusicSarreV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000360 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000360 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sarre
|area= MusicSarreV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4FB9DAD73FF7779A21A20F69F7014643B22C7E89
|texte= Dosing strategies for conversion of haemodialysis patients from short‐acting erythropoiesis stimulating agents to once‐monthly C.E.R.A.: experience from the MIRACEL study
}}
| This area was generated with Dilib version V0.6.33. |  |